CLEVELAND, OH (September 11, 2014) - Ganeden Biotech is proud to announce that a new study has been published in the peer-reviewed publication, AIDS Research and Human Retroviruses. The study was a randomized, double blind and placebo controlled trial in HIV positive subjects who consumed either 2 billion CFU of GanedenBC30 daily or a matching placebo for 90 days.
This study demonstrated that GanedenBC30 supports both digestive and immune health in HIV subjects. The study also provided additional evidence that even in an immune-compromised subject group, there is an absence of safety concerns when consuming GanedenBC30 on a daily basis.
"HIV infection has a profound impact on the gastrointestinal immune system, which many scientists believe to be central to the development of AIDS," adds Dr. Otto Yang, Scientific Director of the AIDS Healthcare Foundation and Professor, Associate Chief of Infectious Diseases at UCLA. "This study demonstrates that probiotics may be a means to beneficially support the GI immune system in HIV subjects."
"This research further builds on the science supporting the benefits of GanedenBC30," said David Keller, VP of Scientific Operations at Ganeden Biotech. "Now not only do we have data that GanedenBC30 is safe for individuals with a healthy immune system, but this study provides evidence which supports safety in an immune-compromised population ". To request the full study, please click here .
About Ganeden Biotech
Ganeden Biotech is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, and now personal care ingredients markets. Ganeden is best known for GanedenBC30 (Bacillus coagulans GBI-30, 6086), its patented, FDA recognized as GRAS, highly stable probiotic ingredient. Ganeden's newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden Biotech and licensing opportunities visit GanedenBiotech.com.
* Ganeden Biotech intends, markets, and sells BC30 solely as a food, beverage and companion animal ingredient, and not as a drug ingredient or treatment.
About GanedenBC30
GanedenBC30® (Bacillus coagulans GBI-30, 6086), Ganeden Biotech's patented probiotic ingredient can be found in more than 100 leading food, beverage and companion animal products throughout the world. Unlike most other probiotic strains, GanedenBC30 is highly stable and allows the organism to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid. The efficacy of GanedenBC30 is backed by 18 published studies showing digestive and immune support and GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any food or beverage product that is heated, frozen or exposed to high pressure..including all hot or refrigerated beverages! GanedenBC30 is the only probiotic to have monograph for testing and identification published by the USP. For more information, please visit GanedenBiotech.com or GanedenBC30.com.
Help employers find you! Check out all the jobs and post your resume.
